MaxCyte signed a strategic platform license (SPL) with Walking Fish Therapeutics which focuses on B cell-based therapeutics. Walking Fish obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive platform licensing fees, clinical milestone payments and sales-based payments.

“We are delighted to partner with Walking Fish to help advance their B cell platform and support their innovative approach to develop novel therapies for the treatment of serious diseases,” said Doug Doerfler, president and CEO of MaxCyte.

Walking Fish is a privately held biotechnology company discovering and developing therapeutics that harness the power of B cells as protein factories and immune modulators. Walking Fish has created a technology platform addressing enzyme replacement therapies, cancer, autoimmune disease, and recombinant antibody production. Walking Fish’s first program, WFX-001, employs B cells as protein factories to generate a deficient enzyme in Fabry disease.

Axolotl, the “walking fish.” [Paul Starosta/Getty Images]
MaxCyte’s ExPERT instrument portfolio is an electroporation technology for scalable cell engineering, according to the company. Walking Fish is MaxCyte’s 20th strategic partnership overall, each of which generates pre-commercial milestone revenue and the vast majority of which include sales-based payments, noted Doerfler.

“Walking Fish draws its inspiration from the remarkable regenerative capacity of the Axolotl, colloquially known as a Walking Fish,” notes the company website.

Previous articleWhole Genome Sequencing for Cancer Arrives in the U.S. with Genome Insight
Next articleNovel Multiple Sclerosis Biological Pathway Uncovered